title: Does site-specific labelling and individual processing of sextant biopsies improve the accuracy of prostate biopsy in predicting pathological stage in patients with T1c prostate cancer?
abstract: OBJECTIVE
  To evaluate whether individual labelling and processing of the sextant of origin improves the accuracy of prostate biopsy in predicting the final pathological stage after radical prostatectomy in patients with T1c prostate cancer.
  
  
  METHODS
  The charts of 386 patients treated for prostate cancer by radical prostatectomy between January 1996 and June 1999 were reviewed. In all, 124 patients fulfilled the following inclusion criteria: no abnormality on digital rectal examination (DRE) or transrectal ultrasonography, a prostate specific antigen (PSA) level before biopsy of < or = 20 ng/mL, and prostate cancer diagnosed after one set of random sextant biopsies, with the cores being submitted in six separate containers individually labelled for the sextant of origin.
  
  
  RESULTS
  Within this series of patients with a low tumour burden, the preoperative PSA, biopsy Gleason score and unilateral vs bilateral involvement were not significant predictors of disease extension. The percentage of positive cores and the number and topography of positive sextants were both statistically significant predictors of organ-confined disease. Although these two variables appeared to be statistically equivalent on a first analysis in the overall series, a subgroup of patients was identified who benefited from the complete topographical information, i.e. those 52 (42%) patients with a Gleason score of < 7, 25-75% positive biopsies and < or =3 positive sextants.
  
  
  CONCLUSIONS
  These results support the individual labelling of biopsy cores in selected patients with a normal DRE and a moderately elevated PSA, as it helps to better predict the final pathological stage. This substantial benefit outweighs the additional effort by the pathologist.
authors.affiliation: Division of Urology and Department of Pathology, Cliniques Universitaires St-Luc, Université catholique de Louvain, Brussels, Belgium. bertrand.tombal@fymu.ucl.ac.be
authors.forename: B
authors.initials: B
authors.lastname: Tombal
authors.forename: N
authors.initials: N
authors.lastname: Tajeddine
authors.forename: J-P
authors.initials: JP
authors.lastname: Cosyns
authors.forename: A
authors.initials: A
authors.lastname: Feyaerts
authors.forename: R
authors.initials: R
authors.lastname: Opsomer
authors.forename: F X
authors.initials: FX
authors.lastname: Wese
authors.forename: P J
authors.initials: PJ
authors.lastname: Van Cangh
mesh_terms: D000328:Adult; D000368:Aged; D001707:Biopsy, Needle / Q000379:methods / Q000592:standards; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy / Q000379:methods; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology* / Q000601:surgery; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D013194:Staining and Labeling / Q000379:methods / Q000592:standards
chemical_list: D017430:Prostate-Specific Antigen